NLRP3 and inflammatory bowel disease: In medical practice, IBD is mainly treated with antibodies or antagonists that inhibit NLRP3 activation, including IL-1β receptor blocker Rilonacept, IL-18 blocker GSK1070806, NLRP3-related ATPase inhibitor Bay 11-7082, and caspase-1 inhibitor eugenol, some of which have been or will soon enter clinical trials (Ozaki et al., 2015).